OnkoSight Key Features

Key Features

    • Targeted disease panels for lung, CRC, melanoma, MDS, MPNs, AML
    • 5-10 day turnaround time
    • Greater gene and mutation type coverage
    • As little as ~1ng FFPE DNA input
    • Simultaneous testing of common and rare clinically actionable mutations
    • Cost-effectively designed to broaden access
    • Superior sensitivity compared to traditional sequencing methods